- Home
- MTLS vs VNDA Comparison
MTLS vs VNDA Comparison
Compare MTLS & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTLS
- VNDA
- Stock Information
- Founded
- MTLS 1990
- VNDA 2002
- Country
- MTLS Belgium
- VNDA United States
- Employees
- MTLS N/A
- VNDA N/A
- Industry
- MTLS Computer Software: Prepackaged Software
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- MTLS Technology
- VNDA Health Care
- Exchange
- MTLS Nasdaq
- VNDA Nasdaq
- Market Cap
- MTLS 297.1M
- VNDA 282.8M
- IPO Year
- MTLS 2014
- VNDA 2006
- Fundamental
- Price
- MTLS $5.29
- VNDA $4.99
- Analyst Decision
- MTLS Buy
- VNDA Strong Buy
- Analyst Count
- MTLS 1
- VNDA 2
- Target Price
- MTLS $9.50
- VNDA $16.50
- AVG Volume (30 Days)
- MTLS 502.2K
- VNDA 673.5K
- Earning Date
- MTLS 04-24-2025
- VNDA 05-07-2025
- Dividend Yield
- MTLS N/A
- VNDA N/A
- EPS Growth
- MTLS 106.79
- VNDA N/A
- EPS
- MTLS 0.24
- VNDA N/A
- Revenue
- MTLS $276,182,835.00
- VNDA $198,772,000.00
- Revenue This Year
- MTLS $6.55
- VNDA $14.36
- Revenue Next Year
- MTLS $9.21
- VNDA $44.53
- P/E Ratio
- MTLS $22.25
- VNDA N/A
- Revenue Growth
- MTLS 4.15
- VNDA 3.18
- 52 Week Low
- MTLS $4.70
- VNDA $3.71
- 52 Week High
- MTLS $9.69
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- MTLS 35.36
- VNDA 57.32
- Support Level
- MTLS $4.87
- VNDA $4.84
- Resistance Level
- MTLS $5.35
- VNDA $5.16
- Average True Range (ATR)
- MTLS 0.19
- VNDA 0.23
- MACD
- MTLS 0.08
- VNDA 0.02
- Stochastic Oscillator
- MTLS 72.41
- VNDA 66.10
About MTLS Materialise NV
Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, Poland, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.